These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34048893)

  • 21. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
    Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
    Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2 Growth in Cell Culture.
    Shema Mugisha C; Vuong HR; Puray-Chavez M; Bailey AL; Fox JM; Chen RE; Wessel AW; Scott JM; Harastani HH; Boon ACM; Shin H; Kutluay SB
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A high-throughput response to the SARS-CoV-2 pandemic.
    Rasmussen L; Sanders S; Sosa M; McKellip S; Nebane NM; Martinez-Gzegozewska Y; Reece A; Ruiz P; Manuvakhova A; Zhai L; Warren B; Curry A; Zeng Q; Bostwick JR; Vinson PN
    SLAS Discov; 2024 Jul; 29(5):100160. PubMed ID: 38761981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A fluorescence-based high throughput-screening assay for the SARS-CoV RNA synthesis complex.
    Eydoux C; Fattorini V; Shannon A; Le TT; Didier B; Canard B; Guillemot JC
    J Virol Methods; 2021 Feb; 288():114013. PubMed ID: 33166547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate.
    Legare S; Heide F; Bailey-Elkin BA; Stetefeld J
    J Biol Chem; 2022 Apr; 298(4):101739. PubMed ID: 35182525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced microscopy technologies enable rapid response to SARS-CoV-2 pandemic.
    Cortese M; Laketa V
    Cell Microbiol; 2021 Jul; 23(7):e13319. PubMed ID: 33595881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Chen KY; Krischuns T; Varga LO; Harigua-Souiai E; Paisant S; Zettor A; Chiaravalli J; Delpal A; Courtney D; O'Brien A; Baker SC; Decroly E; Isel C; Agou F; Jacob Y; Blondel A; Naffakh N
    Antiviral Res; 2022 May; 201():105272. PubMed ID: 35278581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spheroids and organoids as humanized 3D scaffold-free engineered tissues for SARS-CoV-2 viral infection and drug screening.
    Kronemberger GS; Carneiro FA; Rezende DF; Baptista LS
    Artif Organs; 2021 Jun; 45(6):548-558. PubMed ID: 33264436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target-Specific Drug Discovery of Natural Products against SARS-CoV-2 Life Cycle and Cytokine Storm in COVID-19.
    Lee M; Park J; Cho IH
    Am J Chin Med; 2022; 50(4):927-959. PubMed ID: 35729089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.